drugset / Trial / NCT01315886
Conversion From Fast Acting Oral Opioids to Abstral®
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to evaluate safety and efficacy when using a novel dose conversion strategy to switch from immediate release oral opioids to sublingual (SL) fentanyl (Abstral) for treatment of breakthrough cancer pain (BTcP).
Timeline
- Start
- 2011-02-21
- Primary completion
- 2011-12-07
- Completion
- 2011-12-07
Outcome
Outcome not reported
Stopped (Enrollment): “Recruitment difficulties”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Fentanyl | Other / unclassified | — | Other |
Indications
No indication recorded.